Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Inclusion Criteria:

• Currently enrolled and receiving treatment in an Incyte-sponsored clinical study ofparsaclisib.

• Currently tolerating treatment in the parent Protocol.

• Currently receiving clinical benefit from treatment with parsaclisib as monotherapyor in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determinedby the investigator.

• Has at least stable disease, as determined by the investigator.

• Has demonstrated compliance, as assessed by the investigator, with the parentProtocol requirements.

• Willingness and ability to comply with scheduled visits, treatment plans, includingPJP prophylaxis, and any other study procedures indicated in this Protocol.

• Willingness to avoid pregnancy or fathering children

• Ability to comprehend and willingness to sign an ICF

Exclusion Criteria:

• Has been permanently discontinued from study treatment in the parent Protocol forany reason.

• Able to access parsaclisib as monotherapy or in combination with itacitinib,ruxolitinib, or ibrutinib therapy outside a clinical study.

• Participants with an uncontrolled intercurrent illness or any concurrent conditionthat, in the investigator's opinion, would jeopardize the safety of the participantor compliance with the Protocol.

• Pregnant or breastfeeding women.